Free Trial

This company has been marked as potentially delisted and may not be actively trading.

GX Acquisition (GXGX) Competitors

GXGX vs. XOMA, ABEO, PHAT, TRDA, IMMP, HRTX, NGNE, TERN, NATR, and GOSS

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include XOMA (XOMA), Abeona Therapeutics (ABEO), Phathom Pharmaceuticals (PHAT), Entrada Therapeutics (TRDA), Immutep (IMMP), Heron Therapeutics (HRTX), Neurogene (NGNE), Terns Pharmaceuticals (TERN), Nature's Sunshine Products (NATR), and Gossamer Bio (GOSS). These companies are all part of the "medical" sector.

GX Acquisition vs.

XOMA (NASDAQ:XOMA) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.

GX Acquisition has a net margin of 0.00% compared to XOMA's net margin of -151.34%. XOMA's return on equity of -24.95% beat GX Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA-151.34% -24.95% -9.64%
GX Acquisition N/A -985.20%-6.02%

95.9% of XOMA shares are held by institutional investors. Comparatively, 61.7% of GX Acquisition shares are held by institutional investors. 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, XOMA had 13 more articles in the media than GX Acquisition. MarketBeat recorded 13 mentions for XOMA and 0 mentions for GX Acquisition. XOMA's average media sentiment score of 0.69 beat GX Acquisition's score of 0.00 indicating that XOMA is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Positive
GX Acquisition Neutral

XOMA has higher revenue and earnings than GX Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$13.05M22.78-$40.83M-$1.15-21.60
GX AcquisitionN/AN/A-$49.26MN/AN/A

XOMA received 440 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 65.58% of users gave XOMA an outperform vote.

CompanyUnderperformOutperform
XOMAOutperform Votes
442
65.58%
Underperform Votes
232
34.42%
GX AcquisitionOutperform Votes
2
100.00%
Underperform Votes
No Votes

XOMA presently has a consensus price target of $69.50, suggesting a potential upside of 179.85%. Given XOMA's stronger consensus rating and higher probable upside, equities research analysts plainly believe XOMA is more favorable than GX Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

XOMA has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.

Summary

XOMA beats GX Acquisition on 12 of the 15 factors compared between the two stocks.

Get GX Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$89.48M$6.47B$5.31B$8.28B
Dividend YieldN/A2.64%5.20%4.10%
P/E RatioN/A8.9026.7319.58
Price / SalesN/A257.08387.44119.65
Price / CashN/A65.8538.2534.62
Price / Book17.796.406.744.47
Net Income-$49.26M$143.98M$3.23B$248.22M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXGX
GX Acquisition
N/A$2.49
+18.6%
N/A-39.7%$89.48MN/A0.00N/AGap Down
XOMA
XOMA
4.067 of 5 stars
$26.60
-3.2%
$69.50
+161.3%
-0.4%$328.85M$13.05M-7.6410Insider Trade
High Trading Volume
ABEO
Abeona Therapeutics
3.7866 of 5 stars
$6.42
+3.0%
$18.50
+188.2%
+53.4%$313.30M$3.50M-2.39N/ATrending News
Analyst Revision
High Trading Volume
PHAT
Phathom Pharmaceuticals
3.8361 of 5 stars
$4.38
-0.2%
$17.60
+301.8%
-59.1%$305.79M$81.86M-0.77110
TRDA
Entrada Therapeutics
3.1101 of 5 stars
$8.24
+2.9%
$25.67
+211.5%
-52.4%$304.00M$172.22M5.18110News Coverage
Analyst Forecast
Analyst Revision
IMMP
Immutep
1.2624 of 5 stars
$2.01
-1.5%
$7.00
+248.3%
-36.9%$293.54M$5.14M0.002,021Analyst Upgrade
HRTX
Heron Therapeutics
3.8199 of 5 stars
$1.92
flat
$5.50
+186.5%
-46.1%$292.92M$148.52M-10.67300Analyst Downgrade
NGNE
Neurogene
2.3473 of 5 stars
$18.55
-5.0%
$44.60
+140.4%
-44.3%$278.39M$925,000.00-4.2690Analyst Forecast
Gap Up
TERN
Terns Pharmaceuticals
4.0883 of 5 stars
$3.15
flat
$15.63
+396.0%
-50.4%$275.11MN/A-2.6740News Coverage
Positive News
Gap Down
NATR
Nature's Sunshine Products
2.7467 of 5 stars
$14.66
-1.5%
$18.33
+25.1%
-7.6%$269.03M$456.62M16.66850
GOSS
Gossamer Bio
3.7508 of 5 stars
$1.18
+8.3%
$7.75
+556.8%
+81.7%$268.12M$114.70M-3.69180Analyst Revision

Related Companies and Tools


This page (NASDAQ:GXGX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners